Biocytogen Pharmaceuticals Co. Ltd. and Ctm Biotech Co. Ltd. have reported progress in the development of a trispecific T-cell engager for an intracellular target.
From previous reports, there is evidence that cancer cells overexpress inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (ITPRIPL1) to evade the immune system and promote tumor growth. Tissue samples from patients with non-small-cell lung cancer (NSCLC) were collected and used for studying the expression (intensity and extent) patterns of ITPRIPL1 and its diagnostic and prognostic value in this cancer type.
Senti Biosciences Inc. has received clearance of its IND application from the FDA for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33- and/or FLT3-expressing hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome, while sparing healthy bone marrow cells.
Fused pyrimidine compounds acting as menin (MEN1)/MLL interaction inhibitors have been described in a Biomea Fusion Inc. patent and reported to be useful for the treatment of cancer, osteoporosis, autoimmune and inflammatory diseases, among others.
Researchers from Sichuan University and Chengdu Normal University have reported the discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer (TNBC).
PI3Kα H1047R accounts for one-third of all PI3Kα mutations and is associated with treatment resistance to targeted therapies in breast cancer treatment. In addition, treatment with selective PI3Kα inhibitors often results in significant adverse events such as hyperglycemia due to on-target toxicity.
Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism.
Autologous chimeric antigen receptor (CAR) T-cell therapy has been one of the most recent successes in cancer treatment, but limitations, such as manufacturing, costs or antigen escape in therapies directed against only one target that leads to resistance, highlight the need for new approaches. Classical natural killer T (NKT) cells engineered to express CARs constitute a novel type of allogeneic therapy that does not require T-cell receptor (TCR) gene editing, thus avoiding graft-vs.-host disease (GVHD).
Haisco Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
RSS
